Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
33.39
+0.54 (1.64%)
Jul 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 32.03 - 33.67
52 week 27.01 - 44.38
Open 32.92
Vol / Avg. 944,463.00/1.04M
Mkt cap 1.30B
P/E 18.09
Div/yield     -
EPS 1.85
Shares 40.06M
Beta 1.27
Inst. own 88%
Aug 4, 2016
Q2 2016 Emergent BioSolutions Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Emergent BioSolutions Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 29, 2016
Emergent BioSolutions Inc at Three Part Advisors East Coast IDEAS Investor Conference - Webcast
Jun 10, 2016
Emergent BioSolutions Inc at Jefferies Healthcare Conference - Webcast
May 20, 2016
Emergent BioSolutions Inc Annual Shareholders Meeting (Estimated)
May 19, 2016
Emergent BioSolutions Inc Annual Shareholders Meeting - Webcast
May 12, 2016
Emergent BioSolutions Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 5, 2016
Q1 2016 Emergent BioSolutions Inc Earnings Call - Webcast
May 5, 2016
Q1 2016 Emergent BioSolutions Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 3.60% 12.03%
Operating margin 7.71% 18.37%
EBITD margin - 25.13%
Return on average assets 1.54% 6.36%
Return on average equity 2.41% 10.36%
Employees 1,292 -
CDP Score - -

Address

400 Professional Dr Ste 400
GAITHERSBURG, MD 20879-3457
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Daniel J Abdun-Nabi President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Executive Vice President - Corporate Services Division, Chief Financial Officer and Treasurer
Age: 57
Bio & Compensation  - Reuters
Adam Havey Executive Vice President and President - BioDefense Division
Age: 44
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Jerome M. Hauer Independent Director
Age: 63
Bio & Compensation  - Reuters
George A. Joulwan USA Independent Director
Age: 75
Bio & Compensation  - Reuters